{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:53:43Z","timestamp":1786622023591,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.clinthera.2012.12.005","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T04:15:40Z","timestamp":1358223340000},"page":"4-27","source":"Crossref","is-referenced-by-count":30,"title":["Rivaroxaban: An Oral Factor Xa Inhibitor"],"prefix":"10.1016","volume":"35","author":[{"given":"Tyan F.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Ganetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Spinler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.12.005_bib1","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2012.12.005_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1160\/TH09-06-0361","article-title":"The clinical implications of new oral anticoagulants: Will the potential advantages be achieved?","volume":"103","author":"Phillips","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.12.005_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1538-7836.2007.02429.x","article-title":"In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban","volume":"5","author":"Gerotziafas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.12.005_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2141.2010.08433.x","article-title":"The impact of elective knee\/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation","volume":"15","author":"Green","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2012.12.005_bib12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.12.005_bib13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CPP45335","article-title":"Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban\u2014an oral, direct factor Xa inhibitor\u2014in healthy subjects","volume":"45","author":"Mueck","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.12.005_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.2009.03390.x","article-title":"Safety, pharmacokinetics and pharmacodynamics of single\/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese patients","volume":"68","author":"Zhao","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.12.005_bib17","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","article-title":"Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in health elderly subjects","volume":"24","author":"Kubitza","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2012.12.005_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1160\/TH09-03-0196","article-title":"Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban\u2014an oral, direct factor Xa inhibitor\u2014in elderly Chinese subjects","volume":"103","author":"Jiang","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.12.005_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery","volume":"47","author":"Mueck","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.12.005_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","article-title":"Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.12.005_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2125.2012.04181.x","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes","volume":"74","author":"Xu","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, tolerability, pharmacodynamics of rivaroxaban\u2014an oral, direct factor Xa inhibitor\u2014affected by aspirin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2006.02776.x","article-title":"Rivaroxaban (BAY 59-7939)\u2014an oral, direct factor Xa inhibitor\u2014has no clinically relevant interaction with naproxen","volume":"63","author":"Kubitza","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral direct factor Xa inhibitor, in healthy subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/FJC.0b013e31822f6c2b","article-title":"Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban","volume":"58","author":"Moore","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib28","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2012.12.005_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.12.005_bib30","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.12.005_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.12.005_bib32","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.12.005_bib33","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.12.005_bib34","doi-asserted-by":"crossref","unstructured":"Cohen AT, Spiro TE, B\u00fbller J, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thombolysis 201;31:407\u2013416.","DOI":"10.1007\/s11239-011-0549-x"},{"key":"10.1016\/j.clinthera.2012.12.005_bib35","author":"Cohen"},{"key":"10.1016\/j.clinthera.2012.12.005_bib36","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.12.005_bib37","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.12.005_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.12.005_bib39","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.12.005_bib40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.7326\/0003-4819-132-11-200006060-00002","article-title":"Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement","volume":"132","author":"Heit","year":"2000","journal-title":"Ann Int Med"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.12.005_bib41","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2012.12.005_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-0038-1655902","article-title":"Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind dose-ranging study","volume":"77","author":"Heit","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.12.005_bib43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1302\/0301-620X.91B5.21691","article-title":"Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement","volume":"91","author":"Eriksson","year":"2009","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.clinthera.2012.12.005_bib44","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00228-010-0889-z","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib45","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1161\/STR.0b013e318266722a","article-title":"Oral antithrombotic agents for prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"43","author":"Furie","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2012.12.005_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.12.005_bib47","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease Position Paper","volume":"59","author":"De Caterina","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib48","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2004.05348.x","article-title":"Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome","volume":"128","author":"Veeger","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib49","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1378\/chest.129.5.1155","article-title":"Effect of study setting on anticoagulation control: a systematic review and metaregression","volume":"129","author":"van Walraven","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2012.12.005_bib50","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2012.12.005_bib51","article-title":"Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls","volume":"107","author":"Samama","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.12.005_bib52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1076029611426282","article-title":"Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial","volume":"18","author":"Samama","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.clinthera.2012.12.005_bib53","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1160\/TH10-05-0328","article-title":"Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay","volume":"104","author":"Barrett","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.12.005_bib54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/11599370-000000000-00000","article-title":"Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US 50. payer's perspective","volume":"30","author":"Duran","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2012.12.005_bib55","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3111\/13696998.2011.623203","article-title":"Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective","volume":"14","author":"Duran","year":"2011","journal-title":"J Med Economics"},{"key":"10.1016\/j.clinthera.2012.12.005_bib56","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/erp.11.15","article-title":"Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban","volume":"11","author":"Friedman","year":"2011","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.clinthera.2012.12.005_bib57","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1160\/TH10-01-0071","article-title":"Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada","volume":"104","author":"Diamantopoulos","year":"2010","journal-title":"Thrombosis Haemostasis"},{"key":"10.1016\/j.clinthera.2012.12.005_bib58","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.amjcard.2012.05.011","article-title":"Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation","volume":"110","author":"Lee","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2012.12.005_bib59","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.12.005_bib60","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2012.12.005_bib61","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archinternmed.2012.4026","article-title":"Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome","volume":"172","author":"Komosci","year":"2012","journal-title":"Arch Intern Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812006716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812006716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T08:45:16Z","timestamp":1562575516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812006716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0149291812006716"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.12.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}